FOLFIRINOX Versus OncoSil™ in Addition to FOLFIRINOX in Patients With Locally Advanced Pancreatic Adenocarcinoma

This study sits in a very difficult setting: locally advanced pancreatic cancer, where incremental efficacy is hard to demonstrate and treatment toxicity can blur the signal. The trial is only Phase 2, which limits confidence in robustness, and the primary package combines safety/tolerability with local disease control rate at 16 weeks. That creates two hurdles: the add-on device must not introduce problematic adverse events, and it must also show a convincing tumor-control benefit on top of an already intensive FOLFIRINOX backbone. The endpoint is earlier and softer than overall survival, which slightly improves the chance of a nominally positive readout, but it also increases vulnerability to small-sample noise and assessment variability. Device-plus-chemotherapy studies also carry operational risk around procedure timing and consistent delivery. Primary completion has passed, yet the study is still listed active not recruiting; that is not decisive, but it does not give a clear early-positive disclosure signal. Netting these factors, a clearly positive outcome looks somewhat less likely than not.

TRIPP-FFX is a Phase 2, open-label, randomized trial (n=88, 1:1) comparing OncoSil+FOLFIRINOX vs FOLFIRINOX alone in LAPC. Co-primary endpoints are safety (AE profile) and LDCR at 16 weeks. Last Patient Last Visit completed January 2026; results expected H1 2026 but not yet disclosed. Supporting data is modestly encouraging: the PANCOSIL study showed 20.6-month median OS (vs ~13 months historical) and acceptable safety (10% Grade 3 SADEs). A DDW comparative analysis showed 22-month OS vs 14 months for SBRT. Safety endpoint is likely met based on accumulated data. However, the critical question is whether OncoSil meaningfully improves LDCR over FOLFIRINOX alone in a randomized comparison. FOLFIRINOX is already a potent regimen with reasonable disease control rates in LAPC (~60-70%). With only ~44 patients per arm, the trial is underpowered to detect modest improvements. The sponsor is a micro-cap ($11.7M market cap) with minimal revenue, adding execution risk. Adding an invasive brachytherapy procedure on top of strong chemotherapy may yield only marginal benefit that a small trial cannot reliably detect. Biological plausibility exists but translating to statistical significance at this sample size is uncertain.

This Phase 2 trial tests OncoSil device added to standard FOLFIRINOX chemotherapy in locally advanced pancreatic cancer. The dual primary endpoints are safety/tolerability and Local Disease Control Rate at 16 weeks. Safety endpoints in Phase 2 are typically binary and easier to achieve positive results, as trials usually proceed past initial phases if no major safety signals emerge. The trial is 66 days past primary completion date, suggesting data is likely available or imminent. Pancreatic cancer remains difficult to treat, creating uncertainty on efficacy, but the combination approach has biological rationale. Given safety is a primary endpoint and the trial has progressed to completion, positive results on safety are reasonably likely. However, the LDCR efficacy endpoint carries meaningful uncertainty. Overall, slight positive bias but confidence constrained by Phase 2 limitations and small sample size expectations.

This is a Phase 2 study adding the OncoSil device to standard FOLFIRINOX. The primary endpoint is a composite of safety and Local Disease Control Rate (LDCR) at 16 weeks. While LDCR is a relevant early efficacy signal, it is a surrogate endpoint. The control is historical, not a concurrent randomized arm, which increases bias risk. The study is 'Active Not Recruiting' and primary completion was 66 days ago, suggesting data is being analyzed. The sponsor is a small-cap device company (OSL.AX), which can heighten disclosure and operational risks. The intrinsic probability is below 50% due to the high bar for a positive composite readout in a single-arm design with a novel device.

This phase 2 randomized trial tests OncoSil™ (P-32 microparticles) added to FOLFIRINOX versus FOLFIRINOX alone in locally advanced pancreatic adenocarcinoma, a challenging indication with high phase 2 failure rates (~70% historically) due to aggressive biology and low response durability. Co-primary endpoints are safety/tolerability (AE profile over ~18 months) and 16-week LDCR (local CR/PR/SD). LDCR is an early, investigator-assessed surrogate with limited OS predictivity and vulnerability to bias. Patient population (locally advanced, unresectable) may benefit from local radiotherapy but faces FOLFIRINOX toxicity, complicating safety; device implantation adds procedural AEs. Trial design omits sample size/power details, common in exploratory phase 2 but raises stat sig risk. Execution: primary completion overdue 66 days despite active not recruiting, hinting at data delays, safety concerns, or operational hurdles. Small sponsor (OSL.AX) heightens disclosure risk for marginal results. Brief summary notes no prior randomized data; single-arm priors often inflate expectations. Low bar for 'positive' (sponsor claim) but high hurdles for convincing dual endpoint success yield modest odds.

This Phase 2 trial assesses OncoSil™ combined with FOLFIRINOX in locally advanced pancreatic cancer, a poor-prognosis indication. The dual primary endpoints are Safety/Tolerability and Local Disease Control Rate (LDCR) at 16 weeks. The primary completion date passed in January 2026, with the status 'Active Not Recruiting', suggesting the active intervention phase is complete and data analysis is underway. LDCR is a mechanistically plausible endpoint for a localized radiotherapy device like OncoSil, and prior studies have suggested safety and local control signals. Given the bar for 'positive' results in Phase 2 is often lower than confirmatory Phase 3 trials, the likelihood of meeting safety and a surrogate efficacy endpoint is favorable. The primary risk is definitional ambiguity around what constitutes a 'positive' result for a dual-endpoint study, but the operational maturity significantly reduces execution risk.

Phase 2 pancreatic cancer trials face steep odds. The primary completion date passed 66 days ago with no results disclosed, suggesting potential data cleaning delays or emerging safety concerns. The dual primary endpoint (safety/tolerability + LDCR at 16 weeks) is favorable for sponsor success since safety endpoints are typically achievable, but efficacy signals in LAPC remain historically poor. OncoSil is a novel brachytherapy device requiring implantation—this adds procedural complexity and adverse event risk beyond chemotherapy alone. The 'Active Not Recruiting' status with overdue completion raises disclosure risk of negative or mixed results. FOLFIRINOX is already standard of care; demonstrating additive benefit with acceptable safety for an invasive device is a high bar. Prior pancreatic device trials (e.g., NanoKnife) showed mixed efficacy. Small Australian sponsor with limited regulatory experience increases execution risk.

The TRIPP-FFX trial is an 80-patient randomized study designed to expand the CE mark for the OncoSil device to include its use alongside FOLFIRINOX chemotherapy for locally advanced pancreatic cancer (LAPC). The primary endpoints are Safety and Tolerability, and Local Disease Control Rate (LDCR) at 16 weeks. Crucially, the LDCR endpoint is defined descriptively ('summarised as a count and proportion'), suggesting that formal statistical superiority may not be strictly required for the trial to be deemed a success, lowering the hurdle for a positive readout. Prior clinical data strongly supports a positive outcome. In the single-arm PanCO study, combining OncoSil with chemotherapy (including FOLFIRINOX) yielded a highly compelling 90.5% LDCR in the per-protocol population (82% ITT) at 16 weeks, with an acceptable safety profile. Since OncoSil delivers targeted intratumoral Phosphorous-32 brachytherapy, it directly enhances local control compared to systemic chemotherapy alone. The safety profile has already been established in earlier trials, meaning unexpected severe toxicities are unlikely. Given the trial's status as a label-expansion device study with a descriptive efficacy primary endpoint and robust prior proof-of-concept, the likelihood of a positive result is significantly higher than a typical oncology phase 2 trial. I estimate a 75% probability of a YES resolution.

The trial is in Phase 2, assessing the safety and efficacy of OncoSil™ with FOLFIRINOX chemotherapy for locally advanced pancreatic cancer. The primary endpoints include safety and local disease control rate at 16 weeks. Given the early stage and the specific patient population, there's a moderate chance of positive results, but the complexity of pancreatic cancer treatment and the relatively small sample size typical of Phase 2 trials introduce uncertainty. The sponsor's focus on safety and tolerability also suggests a cautious approach, which might affect the outcome.